Loading...
BYH, I just moved to Greenville with my lovely wife and two precious children and a dog. I was so happy when the...

Trump plan fails to lower drug prices

Trump

President Donald Trump speaks during an event about prescription drug prices with Health and Human Services Secretary Alex Azar, left, in the Rose Garden of the White House in Washington in May.

Loading…

Saturday, July 21, 2018

It has been two months since the president released his road map for lowering drug costs that seems to lead nowhere, and about a month since he predicted the “big drug companies” would announce “voluntary massive” price cuts. Here’s where things stand:

A congressional investigation has found that the drug company Novartis got more out of its $1.2 million payment to Trump’s “personal attorney” Michael Cohen than had been known. Meanwhile, several other drugmakers defied Trump’s lofty prediction by raising their prices substantially, while his administration shot down a proposal that would have helped individual states lower their drug costs.

Taken together, the developments help explain why, a year and a half after Trump took office, prescription drugs cost more than ever.

Let’s start with Novartis: When a lawyer for Stephanie Clifford, the pornographic-film star suing Trump, revealed that the drug company was among those who had made payments to Cohen after the election, Novartis executives insisted they’d had only one meeting before concluding that Mr. Cohen would not be helpful. But Senate Democrats have since found that the company actually had several meetings, that drug-pricing policies were on the agenda and that a number of proposals Novartis pushed for made it into the White House plan.

For his part, Trump made a show of chastising the industry on Twitter when several drugmakers raised their prices this month. He called out Pfizer specifically, saying the company “should be ashamed” of itself. The tweet led to a phone call between the company’s chief executive and the president, after which Pfizer agreed to hold off on those price increases for six months, or until the administration had a chance to put its road map into action.

Trump said the concession was “great news for the American people,” but it might actually be more of a coup for the pharmaceutical industry. By tying its actions to the president’s initiative, Pfizer now has both a stick and a carrot to wield: implement a policy that benefits the industry and maybe the company will abandon its price increases; create one that hurts the industry and the company may raise them again. In any case, the other drugmakers that raised prices left those increases in place.

These machinations would be troubling enough by themselves. But the administration seems intent on blocking states from carrying out a policy that might actually make a dent in the drug-cost problem.

That proposal would have opened the door on allowing state Medicaid programs to deny coverage for certain medications. Private insurance companies, the Department of Veterans Affairs and many other countries with drug prices far lower than ours already do this, but Medicaid is required to cover all federally approved medications, no matter expensive or effective they are. If states were allowed to circumvent this rule, they would be able to avoid paying for pricey new drugs that don’t necessarily work as well. They would also have much more negotiating power because they would be able to walk away from drugs that were overpriced.

“It takes away a substantial tool that a lot of states were hoping to use,” says Rachel Sachs, a law professor and drug policy expert at Washington University in St. Louis. It also points to a hypocrisy, she says. “They’re permissive when it comes to work requirements that put added burden on the vulnerable, but protective when it comes to measures that would strain the pharmaceutical industry.”

It’s unclear where we go from here. The administration’s road map for lowering drug costs was short on details about when or how any of its provisions might take effect. And while there’s no telling what Trump discussed with Pfizer that caused it to temporarily halt planned price increases, the exchanges between Cohen and Novartis hardly inspire good faith.

The good news is that elections are coming, and lawmakers know that Americans are enraged by soaring drug costs. By keeping the pressure on, we may see real change yet.

The New York Times

Loading…

Humans of Greenville

@HumansofGville

Local photographer Joe Pellegrino explores Greenville to create a photographic census of its people.

Editorials

October 16, 2018

This has been a banner season for punishing white-collar crime. Guilty pleas by Michael Cohen, President Donald Trump's former longtime personal lawyer, and criminal convictions and additional guilty pleas in the case of former Trump campaign chairman Paul Manafort have drawn enormous attention.…

Trump Political Fallout

October 15, 2018

Nearly three dozen administration officials have left or been forced out of key posts since President Donald Trump was sworn in last year. Few, if any, will be missed as much as Nikki Haley, who announced her resignation as United Nations ambassador on Tuesday.

For a former South Carolina…

Trump Haley-2

October 14, 2018

It’s the kind of anniversary no one wants to remember. A year ago this past Friday, four inmates at Pasquotank Correctional Institution beat to death four correctional employees in a failed escape attempt.

The brutal murders on Oct. 12, 2017, coming on the heels of the vicious murder of a…

October 13, 2018

It’s sorely tempting to criticize Harnett Central High School Principal Cindy Gordon after she reportedly kicked a student out of a football game for wearing a Donald Trump shirt. But examining this blunder in isolation misses the bigger picture.

The Oct. 5 incident didn’t happen in a…

October 12, 2018

Global progressives are having an anxiety attack over the near-triumph Sunday of Brazil’s conservative presidential candidate Jair Bolsonaro.

After years of corruption and recession, apparently millions of Brazilians think an outsider is exactly what the country needs. Maybe they know more…

Braizl Protest-6

October 11, 2018

Mercury is a noxious byproduct of burning coal. It contaminates fish and, in turn, people, leading to brain damage in infants and small children, as well as serious cardiovascular and central nervous system problems in adults. Restrictions on U.S. power plants have substantially reduced their…

ENERGY-POLICY

October 10, 2018

If anything, the Intergovernmental Panel on Climate Change has a habit of understatement. The U.N. group issues reports so thoroughly scrubbed that they seem cautious in the moment and downright timid in retrospect. That gives their latest and most dire warning added force.

The new IPCC report…

United Nations Climate-15

October 09, 2018

Trying to protect an open internet state by state, rather than by federal law, is a daunting and unwieldy goal.

Unfortunately, it’s also entirely necessary, given that the Trump administration and Congress are more than happy to let internet providers restrict what we — the American…

Net Neutrality

October 08, 2018

Jim Allison lost his mother, a brother, two uncles and a cousin to cancer, but he says he never set out to find a cure for the disease. Like many great scientists, he was driven by “the selfish desire to be the first person on the planet to know something,” as he explained to Houston…

Nobel Medicine

October 07, 2018

“I built what I built myself.”

This boast has long been at the core of the mythology of Donald Trump, Self-Made Billionaire. As the oft-told story goes, young Trump accepted a modest $1 million loan from his father, Fred, a moderately successful real estate developer from Queens, and…

Trump Inheritance Taxes
100 stories in Editorials. Viewing 1 through 10.
«First Page   «Previous Page        
Page 1 of 10
        Next Page»   Last Page»